Kim Bridges joins Halt Medical as President and Chief Executive Officer
Brentwood, CA. (March 22, 2016) / PR Newswire — Halt Medical, a privately held medical device company, developing minimally invasive, uterine sparing solutions for women who suffer from symptomatic fibroids, announced today that Kim Bridges has been appointed Chief Executive Officer and member of the Board of Directors. Ms. Bridges replaces Bret Bero who was serving as the interim CEO for the past seven months.
Ms. Bridges joins the Halt team with nearly 20 years of medical device experience. Prior to Halt, she served at Spectranetics, a leading maker of medical devices used in minimally invasive cardiovascular procedures, as Senior Vice President of the Vascular Intervention business unit, which generated more than $140 million annually in US revenue under her leadership.
“After a comprehensive search process, the board is pleased to have found the best individual to assume leadership of this great organization,” said Miles Arnone, of the Halt Board of Directors and managing director at American Capital. “Ms. Bridges has a track record of strong leadership commercially. This makes her uniquely qualified to lead Halt successfully into the future.”
“I am honored to join this remarkable team and impressed by the progress the company has made in developing this much-needed alternative for patients who suffer from symptomatic fibroids,” said Bridges. “We are an organization led by a purpose – to advance the Acessa procedure for women who desire an alternative to hysterectomy or myomectomy. I intend to serve our physicians and their patients by leading and enabling our teammates to fulfill their passion to make a difference.”
Prior to joining Spectranetics, Ms. Bridges has held several global vice president and management roles in sales, marketing, therapy development and general business management at companies such as Blockade Medical, Stryker Neurovascular, Concentric Medical, Guidant Corporation and Johnson & Johnson. She received her Executive MBA at the University of Southern California Marshall School of Business and BS in Management from Pepperdine University.
Founded in 2004, Halt Medical is a medical device company focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Company has developed and launched the Acessa System and Procedure, using radiofrequency energy to destroy uterine fibroids. The results of both U.S. and international trials have led to the clearance of the product by the FDA for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. As well, the System has CE marking in the European Union and is licensed for sale in Canada. The Company is located in Brentwood, CA.